Opportunities this week:
- We are reiterating our BUY rating on Roche Holdings following promising Phase 1b trials for its obesity and type 2 diabetes drug. (BUY: CHF280 target)
- We are reiterating our BUY rating on Ryanair following the airlines FY24 earnings release. (BUY: €23.40 target)
- We are reiterating our BUY rating on Alphabet following it’s annual I/O developer conference. (BUY: $200 target)